Agios Pharmaceuticals Inc

AGIO

26.530USD

-0.040-0.15%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Agios Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

89 / 392

Overall Ranking

216 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Agios Pharmaceuticals Inc Highlights

StrengthsRisks

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 156.31% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 36.50M.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is -3.80, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 64.77M shares, increasing 0.00% quarter-over-quarter.

Held by HACAX

Star Investor HACAX holds 37.23K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.23.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

38.429

Target Price

+38.73%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Agios Pharmaceuticals Inc is 6.56, ranking 240 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 12.88M, representing a year-over-year increase of 43.69%, while its net profit experienced a year-over-year increase of 110.91%.

Score

Industry at a Glance

Previous score

6.56

Change

0



Financials

6.87

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.63

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.93

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.13

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.22

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Agios Pharmaceuticals Inc is 6.26, ranking 304 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.79, which is -236.88% below the recent high of 5.19 and -104.01% above the recent low of -7.74.

Score

Industry at a Glance

Previous score

6.26

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 89/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Agios Pharmaceuticals Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 32.00, with a high of 48.00 and a low of 20.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Agios Pharmaceuticals Inc is 6.30, ranking 267 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 28.89 and the support level at 25.21, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.34

Change

-0.04

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Agios Pharmaceuticals Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 127.16%, representing a quarter-over-quarter decrease of 0.48%. The largest institutional shareholder is The Vanguard, holding a total of 5.58M shares, representing 9.57% of shares outstanding, with 0.89% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Farallon Capital Management, L.L.C.

5.78M

+0.24%

The Vanguard Group, Inc.

Star Investors

5.59M

-1.36%

BlackRock Institutional Trust Company, N.A.

3.98M

-4.45%

Erste Asset Management GmbH

2.76M

+18.84%

Paradigm BioCapital Advisors LP

2.67M

-5.46%

Wellington Management Company, LLP

2.47M

+485.46%

Commodore Capital LP

2.34M

+0.57%

State Street Investment Management (US)

2.26M

+15.97%

Nomura Investment Management Business Trust

1.96M

+3.03%

T. Rowe Price Associates, Inc.

Star Investors

1.60M

-27.98%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Agios Pharmaceuticals Inc is 3.24, ranking 160 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.92. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Agios Pharmaceuticals Inc

AGIO

6.76 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment